Clinical Trials Logo

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how well they work in treating patients with advanced pancreatic neuroendocrine tumors (PNET) that cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Giving temozolomide together with pazopanib hydrochloride may be an effective treatment for patients with PNET.


Clinical Trial Description

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of temozolomide and pazopanib (pazopanib hydrochloride) combination in patients with advanced PNET. (Phase I) II. Determine the overall response rate (ORR). (Phase II) SECONDARY OBJECTIVES: I. Determine safety and toxicity profile of the combination of temozolomide and pazopanib in this population. (Phase I) II. Describe the pharmacokinetics of temozolomide alone and in combination with pazopanib. (Phase I) III. Observe the ORR. (Phase I) IV. Determine progression-free survival (PFS) and overall survival (OS), disease control rate (DCR), and duration of response (DOR). (Phase II) V. Determine the safety and toxicity profile of the combination in a larger cohort of patients. (Phase II) TERTIARY OBJECTIVES: I. Examine the relationship between tumor blood flow, as measured by perfusion functional computed tomography (f CT), and overall response. II. Correlate the expression of tissue methyl-guanine methyl transferase (MGMT) as measured by immunohistochemistry (IHC) with ORR and PFS. OUTLINE: This is a phase I, dose-escalation study followed by a phase II study. Patients receive temozolomide orally (PO) once daily (QD) on days 1-7 and 15-21 and pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01465659
Study type Interventional
Source Northwestern University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date December 12, 2011
Completion date January 27, 2021

See also
  Status Clinical Trial Phase
Withdrawn NCT02108782 - Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Phase 2
Terminated NCT02273752 - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Phase 2
Terminated NCT00084461 - Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Phase 2
Completed NCT01155258 - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1
Completed NCT00131911 - Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Phase 2
Completed NCT01525082 - Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00655655 - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00093782 - Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Phase 2
Completed NCT00075439 - Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Phase 2
Active, not recruiting NCT01824875 - Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1
Completed NCT02259725 - Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Phase 2
Terminated NCT02031536 - Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Phase 2